[Ip-health] Another comparison of DiMasi and PhRMA clinical trial numbers

Joel Lexchin jlexchin at yorku.ca
Tue Mar 15 20:19:57 PDT 2016


But without knowing what drugs DiMasi looked at we can’t judge their therapeutic value. Also drugs for rare diseases by definition will have small numbers in the trials but since they often measure surrogate outcomes the small numbers don’t necessarily mean large therapeutic gains.

Joel
--
Joel Lexchin MD
Professor 
School of Health Policy and Management
Faculty of Health
York University
4700 Keele St. 
Toronto ON 
Canada M3J 1P3
Tel:		+416-736-2100 x 22119
Fax:		+416-736-5227
E mail:	jlexchin at yorku.ca	





More information about the Ip-health mailing list